MDWD MediWound

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress

YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid®, the company’s enzymatic burn debridement therapy, will be featured in 36 scientific oral and poster presentations delivered by leading burn specialists from across Europe, highlighting its role in advancing burn care.

The presentations include data on pediatric, elderly, and critically burned patients demonstrating consistent benefits in survival, recovery, and scar outcomes, as well as value in infection control and modulation of systemic inflammatory responses. Comparative and long-term studies further support NexoBrid’s superiority over surgical excision, reaffirming its role in both routine care and mass casualty scenarios.

“NexoBrid will be prominently highlighted throughout this year’s EBA Congress, reflecting the extensive clinical data and growing real-world experience across Europe,” said Alicia Torrenova, Vice President of European Operations at MediWound. “We are encouraged to see leading burn specialists share their findings, further establishing NexoBrid as an important therapy in advancing burn care.”

About the European Burns Association

The European Burns Association (EBA), founded in 1981, brings together burn care professionals from across Europe to advance standards of treatment, research, and prevention. As a multidisciplinary forum, the EBA promotes collaboration among physicians, researchers, allied health professionals, and organizations dedicated to improving outcomes for burn patients. Through its biennial congress and ongoing initiatives, the EBA fosters the exchange of knowledge and best practices to benefit the global burn care community.

About NexoBrid®

NexoBrid® is a topically administered, biological orphan drug for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for use in adults and pediatric patients in over 40 countries, including the United States, European Union, and Japan.

NexoBrid development has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C. This contract provided funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT), the randomized, controlled pivotal clinical trial for use in the pediatric population (CIDS), the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT). Additional projects for evaluation of NexoBrid funded under the BARDA contract include establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.

For more information visit and follow us on .

MediWound Contacts:                                                                         Media Contact:

Hani Luxenburg                       Daniel Ferry                                          Ellie Hanson

Chief Financial Officer           Managing Director                               Partner

MediWound Ltd.                      LifeSci Advisors, LLC                          FINN Partners for MediWound

                             



EN
02/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediWound

 PRESS RELEASE

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations...

MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress MediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin, Germany. NexoBrid®, the company’s enzymatic burn debridement therapy, will be f...

MediWound Ltd: 1 director

A director at MediWound Ltd bought 11,200 shares at 17.740USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

MediWound to Present at the H.C. Wainwright 27th Annual Global Investm...

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference. A live webcast of the event will be accessible both and on MediWound’s website,...

 PRESS RELEASE

MediWound Reports Second Quarter 2025 Financial Results and Provides C...

MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-ge...

 PRESS RELEASE

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong L...

MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wound bed preparation as a critical step in the healing process YAVNE, Israel, August 13, 2025 (GLOBE NEWSWIRE) – MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue re...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch